SCHEMBL24364264

SCHEMBL24364264

C[C@H]1CC[C@H](c2cccc(CCN(C)C)c2)NC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 4/20 0.43
HTR7 P34969 5/20 0.40
HTR1A P08908 2/20 0.37
ACHE P22303 1/20 0.36
HTR6 P50406 1/20 0.34
CHRNA7 P36544 1/20 0.34
OPRM1 P35372 4/20 0.33
OPRD1 P41143 4/20 0.33
OPRK1 P41145 4/20 0.33
AOC3 Q16853 1/20 0.33
HRH3 Q9Y5N1 1/20 0.33
KDM4A O75164 1/20 0.33
KDM4B O94953 1/20 0.33
KDM5C P41229 1/20 0.33
KDM5B Q9UGL1 1/20 0.33
DRD2 P14416 1/20 0.32
DRD1 P21728 1/20 0.32
DRD4 P21917 1/20 0.32
DRD5 P21918 1/20 0.32
DRD3 P35462 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30551798 1.00 TAAR1 (0.43) TAAR1HTR7HTR1AACHEHTR6
SCHEMBL25319729 1.00 TAAR1 (0.43) TAAR1HTR7HTR1AACHEHTR6
SCHEMBL24233755 0.92 SIGMAR1 (0.37) TAAR1HTR7
SCHEMBL30469656 0.92 SIGMAR1 (0.37) TAAR1HTR7
SCHEMBL24364939 0.92 SIGMAR1 (0.37) TAAR1HTR7
SCHEMBL25320228 0.88 ALDH1A1 (0.37) TAAR1HTR7ACHE
SCHEMBL24365618 0.83 HRH3 (0.43) TAAR1CHRNA7HRH3
SCHEMBL24364832 0.83 HRH3 (0.43) TAAR1CHRNA7HRH3
SCHEMBL25323362 0.81 HRH3 (0.41) TAAR1HRH3
SCHEMBL30551760 0.81 HRH3 (0.41) TAAR1HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250163048-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2025-05-22 US disclosed
US-20240228478-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2024-07-11 US disclosed
WO-2023146990-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. (US) 2023-08-03 WO disclosed
WO-2023146990-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. (US) 2023-08-03 WO disclosed
US-20220127256-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2022-04-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250163048-A1 COMPOUNDS AND METHODS OF USE RB1, CYP1B1, REN TAAR1 2442/4885HTR7 1509/4885HTR1A 888/4885
US-20220127256-A1 COMPOUNDS AND METHODS OF USE F12, C1R, ABCG2 TAAR1 555/4885HTR7 441/4885HTR1A 937/4885
US-20240228478-A1 COMPOUNDS AND METHODS OF USE F12, C1R, ABCG2 TAAR1 555/4885HTR7 441/4885HTR1A 937/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.